# 48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety

> **NCT00654602** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1500 (estimated)

## Conditions studied

- Dyslipidaemia

## Interventions

- **DRUG:** Rosuvastatin
- **BEHAVIORAL:** Maintenance of specific diet

## Key facts

- **NCT ID:** NCT00654602
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** —
- **Final completion:** 2004-11
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2009-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00654602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00654602, "48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00654602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*